Background The development of immune checkpoint inhibitors (ICIs) represents a paradigm
shift in the treatment of cancers. Despite showing remarkable efficacy, these agents can be …

Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …

PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …

Background Immune-related adverse events (irAEs) from immune checkpoint inhibitors
(ICIs) are sometimes associated with autoantibodies, but we do not know how frequently or …

Abstract Immune-checkpoint-inhibitor (ICI)–associated myotoxicity involves the heart
(myocarditis) and skeletal muscles (myositis), which frequently occur concurrently and are …

While the spectrum of neurological immune checkpoint inhibitor-related adverse events is
expanding, patients' outcomes are not well documented. This study aimed to assess …

Background Management of immune-related adverse events (irAEs) is important as they
cause treatment interruption or discontinuation, more often seen with combination immune …

Immune checkpoint inhibitor (ICI)-related myositis is a rare, potentially fatal condition that
warrants further studies. Its incidence, clinical features, and prognosis remain poorly …

Myocarditis associated with the use of immune checkpoint inhibitors (ICI) is a rare
manifestation of their cardiotoxicity, but is characterized by a high mortality rate. A literature …

Immune checkpoint inhibitors (ICIs), used to treat many advanced cancers, activate the
immune system to elicit an antitumor response. ICIs can also cause immune-related adverse …